Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4088425 | 1.00 | HTT (0.58) | HTTALDH1A1KDM4ECYP3A4CYP2D6 | |
| SCHEMBL27820665 | 0.78 | HTT (0.63) | HTTALDH1A1KDM4ECYP3A4CYP2D6 | |
| SCHEMBL14535437 | 0.77 | HTT (0.71) | HTTALDH1A1KDM4ECYP3A4CYP2D6 | |
| SCHEMBL19658757 | 0.77 | HTT (0.71) | HTTALDH1A1KDM4ECYP3A4CYP2D6 | |
| SCHEMBL13662812 | 0.75 | HTT (0.60) | HTTALDH1A1KDM4ECYP3A4CYP2D6 | |
| SCHEMBL1153625 | 0.75 | HTT (0.60) | HTTALDH1A1KDM4ECYP3A4CYP2D6 | |
| SCHEMBL17966983 | 0.75 | HTT (0.60) | HTTALDH1A1KDM4ECYP3A4CYP2D6 | |
| SCHEMBL4862572 | 0.75 | HTT (0.69) | HTTALDH1A1KDM4ECYP3A4CYP2D6 | |
| SCHEMBL13241282 | 0.74 | MEN1 (0.46) | ALDH1A1KDM4EKMT2AMEN1 | |
| SCHEMBL23000164 | 0.74 | HTT (0.62) | HTTALDH1A1KDM4ECYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203697-A1 | HETEROCYCLIC TYPE CINNAMIDE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| EP-2019094-A1 | HETEROCYCLIC TYPE CINNAMIDE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2009-01-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203697-A1 | HETEROCYCLIC TYPE CINNAMIDE DERIVATIVE | CLIC4, NR3C2, MAN2B1 | HTT 3885/4885ALDH1A1 159/4885KDM4E 3267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.